

Harm Reduction Fentanyl Test Strips

Analytical Performance Evaluation



Summary and Explanation

Fentanyl is an extremely fast acting synthetic opioid related to the phenylpiperidians. It has the brand names of Sublimaze, Actiq, Durogestic, Fentora and others. Fentanyl is approximately 100 times more potent than morphine, with 100 micrograms of fentanyl approximately equivalent to 10 mg of morphine or 75 mg of meperidine in analgesic activity (1,2). Fentanyl is a potent narcotic analgesic with rapid onset and short duration of action. Historically, it has been used to treat chronic breakthrough pain and is commonly used pre-procedures. Illicit use of pharmaceutical fentanyl first appeared in the mid- 1970s. Because the effects of fentanyl last for only a very short time, it is even more addictive than heroin. The regular users may become addicted very quickly. Fentanyl is much more potent than heroin, and tends to produce significantly worse respiratory depression, making it somewhat more dangerous than heroin to users. The overdose of fentanyl has caused death. In humans, the drug appears to be metabolized primarily by oxidative N-dealkylation to Norfentanyl and other inactive metabolites that do not contribute materially to the observed activity of the drug. Within 72 hours of intravenous (IV) administration, approximately 75% of the dose is excreted in urine, mostly as metabolites with <10% representing unchanged drug (3,4).


Fentanyl is a controlled substance. As an analgesic, fentanyl can be used for cancer pain treatment. It can also be used to treat severe chronic pain that requires opioid analgesics. Fentanyl can also be abused in a manner similar to other opioid antagonists (legal or illicit). Illegal drug consumption contributes to many accidents, injuries and medical conditions.

Jiangsu Well Biotech Ltd. a immunoassay manufacturer, has developed a fentanyl test strip designed to facilitate the rapid, low-cost, and accurate detection of fentanyl drug residues on suspected surface, in powder or in liquid. It is designed to integrate the collection of sample and lateral flow immunoassay screen testing in one single device. As fentanyl is often mixed with other illicit substances and cutting agents, researchers have conducted the following studies to assess the fentanyl test strip's analytical sensitivity, its potential cross-reactivity in the presence of high concentrations of common cutting agents and illicit compounds.

Equipment Test Procedure

1. Open the device kit and remove the test strip from the sealed pouch.
2. **Powder Form:** Dab the powder with the end of the strip or crush drug to a powder then swipe with the end of the strip. Add 3 drops of buffer onto sample pad until the fluid shows up in the window area.

Liquid Form: Add one drop of liquid sample onto the sample pad of the strip. Then add one or two drops of buffer onto sample pad until the fluid shows up in the window area.



3. Lay the device on a flat surface and read results in approximately 5 minutes. Do not read results after 10 minutes.

Fentanyl Precision

For precision test of fentanyl drugs, dilute fentanyl standards at different concentrations (0, 50%, 150%, 300% and 600% cutoff) into negative buffer solutions. For each concentration, a total of 10 tests were conducted to verify the testing performance. Each study device was tested in accordance with the instructions.

Test Strip	0ng/mL	0.5ng/mL	1.5ng/mL	3ng/mL	6ng/mL
1	Neg	Neg	Pos	Pos	Pos
2	Neg	Neg	Pos	Pos	Pos
3	Neg	Neg	Pos	Pos	Pos
4	Neg	Neg	Pos	Pos	Pos
5	Neg	Neg	Pos	Pos	Pos
6	Neg	Neg	Pos	Pos	Pos
7	Neg	Neg	Pos	Pos	Pos
8	Neg	Neg	Pos	Pos	Pos
9	Neg	Neg	Pos	Pos	Pos
10	Neg	Neg	Pos	Pos	Pos

The Harm Reduction device detects Fentanyl at the cutoff of 1 ng/ml.

Analytical Specificity Research (Cross-Reactivity)

In the study 56 fentanyl analogs were tested using the Fentanyl Test Strip. The specificity was evaluated by adding fentanyl analogs to negative buffer. The results are expressed as the lowest concentration of the compound, in ng/mL, that produced a positive result. Percent cross reactivity of a compound is calculated by dividing the cutoff concentration by the lowest concentration required to obtain a positive result and the multiplying by 100%. Each study device was tested in accordance with the instructions.

Fentanyl Analog Compounds showing various degrees of cross-reactivity.

Compound Name	Concentration ng/mL	Cross Reactivity %
<i>o</i> -Fluorofentanyl	2.5ng/mL	40%
<i>p</i> -Fluorobutyryl fentanyl	10ng/mL	10%
Tetrahydrofuran fentanyl	500ng/mL	0.2%
2-Thiofuranyl fentanyl	50ng/mL	2%
4-Piperidone	2500ng/mL	0.04%
2',4'-dimethoxy Fentanyl	2.5ng/mL	40%
3',4'-dimethoxy Fentanyl	1ng/mL	100%
<i>meta</i> -fluoro Acrylfentanyl	2.5ng/mL	40%
<i>para</i> -chloro Furanyl fentanyl 3-furancarboxamide	5ng/mL	20%
Thiophene fentanyl 3-thiophenecarboxamide	25ng/mL	4%
3'-Fluorofentanyl	2.5ng/mL	40%
<i>ortho</i> -fluoro Valeryl fentanyl	500ng/mL	0.2%
4-methyl Fentanyl	5ng/mL	20%
Cyclopropaneacetyl fentanyl	2.5ng/mL	40%
<i>para</i> -Chloroacetyl fentanyl	5ng/mL	20%
<i>para</i> -hydroxy Butyryl fentanyl	2.5ng/mL	40%
2'-Fluoro <i>ortho</i> -Fluorofentanyl	10ng/mL	10%
<i>meta</i> -methoxy Furanyl fentanyl	25ng/mL	4%
3'-fluoro <i>ortho</i> -Fluorofentanyl	5ng/mL	20%
2',3'-dimethoxy Fentanyl	1ng/mL	100%
2',6'-dimethoxy Fentanyl	2.5ng/mL	40%
3',5'-dimethoxy Fentanyl	1ng/mL	100%
Acetyl norfentanyl	10ng/mL	10%
Acetyl- α -methyl fentanyl	5ng/mL	20%
Acryl fentanyl	10ng/mL	10%
α -methyl fentanyl	1ng/mL	100%
Benzyl fentanyl	2.5ng/mL	40%
β -hydroxythio fentanyl	5ng/mL	20%
Cyclopropyl fentanyl	1ng/mL	100%
4-Fluoroisobutyryl Fentanyl	50ng/mL	2%
Methoxyacetyl fentanyl	12.5ng/mL	8%
4-methoxybutyryl fentanyl (<i>para</i>)	400ng/mL	0.25%
4'-methyl acetyl fentanyl	25ng/mL	4%

<i>3'-methyl Fentanyl</i>	10ng/mL	10%
<i>N-methyl norfentanyl</i>	1.5ng/mL	66.7%

Fentanyl Analog Compounds showing no cross-reactivity.

<i>Isotonitazene</i>	<i>4-Anilino-1-Boc-piperidine</i>
<i>O-Desmethyl-cis-tramadol</i>	<i>Norcarfentanil</i>
<i>Benzoyl fentanyl (Phenyl fentanyl)</i>	<i>2-fluoro Viminol</i>
<i>Despropionyl para-Fluoro fentanyl</i>	<i>4-Anilino-1-benzylpiperidine</i>
<i>N-Phenethyl-4-piperidone(NPP)</i>	<i>Etonitazene</i>
<i>4-ANPP</i>	<i>AP-238</i>
<i>Despropionyl ortho-Fluorofentanyl</i>	<i>2,3-Benzodioxole fentanyl</i>
<i>AP-237</i>	<i>N-Benzyl-4-piperidone</i>
<i>2-methyl AP-237</i>	<i>Brorphine</i>
<i>Tianeptine</i>	<i>4-Anilinopiperidine</i>
<i>Piperidylthiambutene</i>	

Within the study there were 35 compounds that demonstrated cross-reactivity to various degrees and are able to be detected by the Fentanyl Test Strip. The other remaining 21 analog compounds did not cross react with the Fentanyl Test Strips at concentrations of up to 100 µg/mL.

The following opioids compounds were tested at a concentration of 100ug/mL.

<i>6-Acetyl morphine</i>	<i>Naltrexone</i>
<i>Amphetamine</i>	<i>Norbuprenorphine</i>
<i>Buprenorphine</i>	<i>Norcodeine</i>
<i>Buprenorphineglucuronide</i>	<i>Norketamine</i>
<i>Codeine</i>	<i>Normeperidine</i>
<i>Dextromethorphan</i>	<i>Normorphine</i>
<i>Dihydrocodeine</i>	<i>Noroxycodone</i>
<i>EDDP</i>	<i>Oxycodone</i>
<i>EMDP</i>	<i>Oxymorphone</i>
<i>Fluoxetine</i>	<i>Pentazocine (Talwin)</i>
<i>Heroin</i>	<i>Pipamperone</i>
<i>Hydrocodone</i>	<i>Risperidone</i>
<i>Hydromorphone</i>	<i>Tapentadol</i>
<i>Ketamine</i>	<i>Thioridazine</i>
<i>Levorphanol</i>	<i>Tilidine</i>
<i>Meperidine</i>	<i>Tramadol</i>
<i>Methadone</i>	<i>Tramadol-O-Desmethyl</i>
<i>Morphine</i>	<i>Tramadol-N-Desmethyl</i>
<i>Morphine-3-glucuronide</i>	<i>Trazodone</i>

Naloxone	
----------	--

Negative results were obtained for all these compounds. There is no cross-reactivity for these compounds using the AllSource Harm Reduction.

References

1. Gutstein HB, Akil H: Chapter 21: Opioid analgesics. In Goodman and Gilman's: The Pharmacological Basis of Therapeutics. Vol. 11. Edited by JGLL Hardman, AG Gilman. New York, McGraw-Hill Book Company Inc. 2006
2. Kerrigan S, Goldberger BA: Opioids. In Principles of Forensic Toxicology. Second Edition. Edited by ZB Levine. Washington DC, AACCPress, 2003, pp 187-205
3. Package insert: DURAGESIC (fentanyl transdermal system). Janssen Pharmaceutica Products. Titusville, NJ. LP, 2006
4. Baselt RC: Disposition of Toxic Drugs and Chemicals in Man. Eighth edition. Foster City, CA. Biomedical Publications, 2008, pp 616-619
5. Legislative Analysis and Public Policy Association Fentanyl Test Strips (MAY 2021)
Julie K. O'Donnell, John Halpin, Christine L. Mabson, Bruce A. Goldberger, R. Matthew Gladden (2017) Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 — 10 States, July–December 2016, Morbidity and Mortality Weekly Report, US Department of Health and Human Services/Centers for Disease Control and Prevention, MMWR / November 3, 2017 / Vol. 66 / No. 43 1197 – 1202
7. Velagapudi V, Sethi R. Illicit Non-Pharmaceutical Fentanyl and Its Analogs: A Short Review of Literature. Kans J Med. 2023 Jan 18;16:25-27. doi: 10.17161/kjm.vol16.18555. PMID: 36703950; PMCID: PMC9872502
8. Wharton R. E. et al (2021) Detection of 30 Fentanyl Analogs by Commercial Immunoassay Kits, Journal of Analytical Toxicology, 2021; 45:111–116

Date: June 14th, 2024

Authors: Wenwen Geng, Xiulan Zhang